NOVARTIS announced new data
from the head-to-head CLEAR
study, saying it demonstrated
that Cosentyx (secukinumab) was
significantly more efficacious than
ustekinumab in achieving sustained
skin clearance (PASI 90 response) at
52 weeks for adults.The above article was sent to subscribers in Pharmacy Daily's issue from 08 Mar 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 08 Mar 16
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.